Effect of telmisartan 80 mg once daily on 24-h blood pressure profile in patients with mild-to-moderate hypertension failing to respond to prior antihypertensive therapy
Authors: Parra Carrillo, J.Z.1; Fernández, M.2; Barrera, M.3; Bahena, J.4; Estrella, M.4; Olivares Ruiz, R.5; Lepe, L.6; Arriaga, R.7; Bonilla, C.1; Fonseca, S.1; Miranda, S.8; Segovia, C.8; García Luna Viesca, M.D.C.8
Source: International Journal of Clinical Practice, Volume 58, Supplement 145, December 2004 , pp. 9-15(7)
Publisher: Blackwell Publishing
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
Summary Blood pressure is not adequately controlled in almost 50% of patients with hypertension who are in receipt of antihypertensive therapy. This multicentre, prospective, open-label trial was designed to determine whether or not once-daily telmisartan 80 mg reduced blood pressure during the last 6 h of the 24-h dosing interval in patients with mild-to-moderate hypertension who were unresponsive to previous antihypertensive therapy. The study comprised 100 patients (47 males, 53 females) who had failed to respond satisfactorily to prior treatment given for a minimum of 3 months. At screening, 24-h ambulatory blood pressure monitoring (ABPM) was conducted after the patient had been treated with the currently prescribed antihypertensive medication. Following 5 weeks of telmisartan 80 mg treatment, ABPM was repeated. Telmisartan significantly reduced mean systolic blood pressure, diastolic blood pressure (DBP) and pulse pressure compared with previous antihypertensive therapy over each time interval (24-h, morning, night-time and the last 6 h of the dosing interval [2.00 a.m.−8.00 a.m.]) analysed. In addition, more than 90% of patients responded successfully (clinic DBP <90 mmHg or a >10 mmHg reduction in clinic DBP) at the end of telmisartan treatment. In conclusion, telmisartan provides effective blood pressure control throughout the 24-h dosing interval in patients with mild-to-moderate hypertension who were unresponsive to previous antihypertensive medication.Keywords: Telmisartan; ambulatory blood pressure monitoring; angiotensin II receptor blocker; antihypertensives; hypertension
Document Type: Research article
DOI: 10.1111/j.1742-1241.2004.00404.x
Affiliations: 1: Instituto de Investigación Cardiovascular, Universidad de Guadalajara, Hospital Civil `Dr Juan I. Menchaca', Guadalajara 2: Clínica de Hipertensión, Instituto Nacional de la Nutrición y Ciencias Médicas `Salvador Zubirán', México City 3: Clínica Mérida, Mérida, Yucatán 4: Servicio de Cardiología, Hospital Universitario de Monterrey, Nuevo León 5: Hospital `Valentín Gömez Farías' ISSSTE Guadalajara, Jalisco 6: Servicio de Cardiología del Centro Médico Nacional `La Raza', IMSS, México City 7: Hospital de Cardiología del Centro Médico Nacional Siglo XXI IMSS, México City 8: Medical Department, Boehringer Ingelheim Promeco, México
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Click here for Page Help